{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"889"}],"title":"GLAD-Score 2"},{"measurements":[{"groupId":"OG000","value":"75"}],"title":"GLAD-Score 1"},{"measurements":[{"groupId":"OG000","value":"122"}],"title":"GLAD-Score 0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1086"}],"units":"Participants"}],"description":"For SID, immunoglobulin substitution (IgRT) is mandatory only for patients with an IgG level \\< 4g/l (or IgG subclass deficiency) and additionally more than 3 infections or a severe infection (≥ grade 3) and is optional (may be appropriate) if IgG level \\< 4g/l and/or 1-3 less severe infections (≤ grade 2). IgRT is not indicated if patients do not fulfil either condition.\n\nScoring system:\n\nGLAD-Score 2: full guideline adherence GLAD-Score 1: deviations in dose or interval (+/- 10%) or a late start of IgRT (\\>28 days after a severe infection (≥ grade 3).\n\nGLAD-Score 0: IgRT without indication (overuse) or omitted IgRT despite recommendation (underuse). Likewise, 0 points were awarded if both the dose and the interval deviated from the GL recommendations (e.g. underdosed single dose) or if IgRT was not started until more than 3 months after hypogammaglobulinemia and at least one severe infection.","groups":[{"description":"This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analysed.","id":"OG000","title":"Non-interventional Retrospective Observational Study."}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Median study observation period of 18.2 months","title":"Guideline Adherence (GLAD)","type":"PRIMARY","unitOfMeasure":"Participants"}